- Home
- SIGA vs CCAP Comparison
SIGA vs CCAP Comparison
Compare SIGA & CCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- CCAP
- Stock Information
- Founded
- SIGA 1995
- CCAP 2015
- Country
- SIGA United States
- CCAP United States
- Employees
- SIGA N/A
- CCAP N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- CCAP Finance: Consumer Services
- Sector
- SIGA Health Care
- CCAP Finance
- Exchange
- SIGA Nasdaq
- CCAP Nasdaq
- Market Cap
- SIGA 515.1M
- CCAP 562.2M
- IPO Year
- SIGA 1997
- CCAP N/A
- Fundamental
- Price
- SIGA $8.28
- CCAP $13.57
- Analyst Decision
- SIGA
- CCAP Buy
- Analyst Count
- SIGA 0
- CCAP 4
- Target Price
- SIGA N/A
- CCAP $16.38
- AVG Volume (30 Days)
- SIGA 479.2K
- CCAP 204.8K
- Earning Date
- SIGA 11-06-2025
- CCAP 11-10-2025
- Dividend Yield
- SIGA 7.11%
- CCAP 13.63%
- EPS Growth
- SIGA N/A
- CCAP N/A
- EPS
- SIGA 1.14
- CCAP 1.19
- Revenue
- SIGA $179,639,422.00
- CCAP $183,172,000.00
- Revenue This Year
- SIGA N/A
- CCAP N/A
- Revenue Next Year
- SIGA $115.06
- CCAP $1.65
- P/E Ratio
- SIGA $7.27
- CCAP $11.43
- Revenue Growth
- SIGA 3.86
- CCAP N/A
- 52 Week Low
- SIGA $4.95
- CCAP $13.54
- 52 Week High
- SIGA $9.62
- CCAP $20.19
- Technical
- Relative Strength Index (RSI)
- SIGA 46.70
- CCAP 27.89
- Support Level
- SIGA $8.15
- CCAP $13.76
- Resistance Level
- SIGA $9.29
- CCAP $14.41
- Average True Range (ATR)
- SIGA 0.34
- CCAP 0.29
- MACD
- SIGA -0.11
- CCAP -0.16
- Stochastic Oscillator
- SIGA 24.62
- CCAP 10.12
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About CCAP Crescent Capital BDC Inc. Common stock
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.